Aflibercept Treatment with Fluoropyrimidine and Irinotecan Starting before radical surgery in patients with Resistant rectal cancer failing to respond or showing disease progression according to magnetic resonance imaging (MRI) criteria at a six weeks assessment after completion of treatment with neoadjuvant chemoradiation to downstage and facilitate a curative resection.

Trial Profile

Aflibercept Treatment with Fluoropyrimidine and Irinotecan Starting before radical surgery in patients with Resistant rectal cancer failing to respond or showing disease progression according to magnetic resonance imaging (MRI) criteria at a six weeks assessment after completion of treatment with neoadjuvant chemoradiation to downstage and facilitate a curative resection.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 29 Oct 2014

At a glance

  • Drugs Aflibercept (Primary) ; Irinotecan (Primary) ; Fluoropyrimidine derivatives
  • Indications Adenocarcinoma; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms AT FIRST
  • Most Recent Events

    • 25 Oct 2014 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by United Kingdom Clinical Research Network record.
    • 11 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top